Another study also shows that sitagliptin reduces serum CRP levels via inhibiting the activation of NF-κB in T2DM, partially improving endothelial dysfunction in patients with uncontrolled diabetes and CVD [40]. Here, CRP is linked to endothelial dysfunction.